

# **A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure**

Birmingham, Alabama, United States  
La Jolla, California, United States  
Long Beach, California, United States  
San Diego, California, United States  
Sylmar, California, United States  
Newark, Delaware, United States  
Jacksonville, Florida, United States  
Miami, Florida, United States  
Augusta, Georgia, United States  
Iowa City, Iowa, United States  
Alexandria, Louisiana, United States  
Boston, Massachusetts, United States  
Kansas City, Missouri, United States  
St. Louis, Missouri, United States  
Bronx, New York, United States  
New York, New York, United States  
Winston Salem, North Carolina, United States  
Columbus, Ohio, United States  
Oklahoma City, Oklahoma, United States  
Philadelphia, Pennsylvania, United States  
Charleston, South Carolina, United States  
Rapid City, South Dakota, United States  
Germantown, Tennessee, United States  
Tullahoma, Tennessee, United States  
Houston, Texas, United States  
San Antonio, Texas, United States  
Salt Lake City, Utah, United States  
Tacoma, Washington, United States  
Waukesha, Wisconsin, United States  
Aalst, , Belgium  
Leuven, , Belgium  
Aalborg, , Denmark  
Copenhagen, , Denmark  
Hvidovre, , Denmark  
Bad Nauheim, , Germany  
Berlin, , Germany  
Dresden, , Germany  
Köln, , Germany  
München, , Germany  
Budapest, , Hungary  
Debrecen, , Hungary  
Ashkelon, , Israel  
Holon, , Israel  
Jerusalem, , Israel  
Rehovot, , Israel  
Groningen, , Netherlands  
Gdansk, , Poland  
Wrocław, , Poland  
Zabrze, , Poland  
Malmö, , Sweden  
Stockholm, , Sweden  
Örebro, , Sweden  
Glasgow, , United Kingdom  
London, , United Kingdom

The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.